Loading clinical trials...
Loading clinical trials...
Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients < 4 Months of Age
This open label study will assess the pharmacokinetics and the safety and tolerability of Valcyte (valganciclovir) powder for oral solution in neonatal and infant heart transplant patients \< 4 months of age.
Age
0 - 0 years
Sex
ALL
Healthy Volunteers
No
Loma Linda, California, United States
Palo Alto, California, United States
Aurora, Colorado, United States
Atlanta, Georgia, United States
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
St Louis, Missouri, United States
The Bronx, New York, United States
Durham, North Carolina, United States
Cincinnati, Ohio, United States
Start Date
May 1, 2011
Primary Completion Date
September 1, 2013
Completion Date
September 1, 2013
Last Updated
November 2, 2016
17
ACTUAL participants
valganciclovir [Valcyte]
DRUG
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions